FOLFIRINOX
FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer. It is made up of the following four drugs:
- FOL – folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-fluorouracil (5-FU);[1][2]
- F – pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis;
- IRIN – irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and
- OX – oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.
The regimen emerged in 2010 as a new treatment for patients with
In 2013, the U.S. Food and Drug Administration approved protein-bound paclitaxel (also known as nab-paclitaxel, sold as Abraxane) used with gemcitabine. This regimen may be less toxic—but perhaps less effective—alternative to FOLFIRINOX for treating late-stage pancreatic cancer. Differences in the trials, and the lack of a direct trial comparing the two regimens, preclude a final conclusion.[8] In the United Kingdom, the National Institute for Health and Care Excellence (NICE), in a draft guidance issued in 2014, rejected the use of Abraxane in treatment due to concerns of side effects, efficacy, and cost relative to Gemzar (gemcitabine).[10] However, on 18 May 2017 NICE issued a reappraisal for the use of Abraxane in the UK. This was in response to Celgene putting forward a Patient Access Scheme (PAS) proposal, which would bring down the cost of the drug.[11]
See also
References
- PMID 2963229.
- ^ "Leucovorin".
- S2CID 36317669.
- PMID 23657686.
- ^ "FOLFIRINOX". Pancreatic Cancer Association. Archived from the original on 17 September 2013. Retrieved 6 September 2013.
- ^ a b "Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients". National Cancer Institute. 7 June 2011. Retrieved 6 September 2013.
- PMID 21561347.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ^ PMID 24683721.
- S2CID 206074649.
- ^ "The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance" (Press release). National Institute for Health and Care Excellence. 30 December 2014. Retrieved 29 March 2022.
- ^ "Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE" (Press release). National Institute for Health and Care Excellence. 4 August 2017. Retrieved 8 March 2022.